SCHEMBL1643541

SCHEMBL1643541

COc1ccccc1-c1nccc(C(=O)c2ccccc2Cl)c1N

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.51
HPGD P15428 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MAPK13 O15264 1/20 0.44
MAPK12 P53778 1/20 0.44
MAPK11 Q15759 1/20 0.44
LMNA P02545 2/20 0.44
RORB Q92753 3/20 0.43
RECQL P46063 1/20 0.43
KMT2A Q03164 1/20 0.42
CHRNA7 P36544 1/20 0.41
UGCG Q16739 1/20 0.41
RORC P51449 1/20 0.40
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
TDO2 P48775 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ADORA2A P29274 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1643544 0.91 MAPK14 (0.59) MAPK14HPGDRAB9ASMN1; SMN2L3MBTL1
SCHEMBL1642477 0.90 MAPK14 (0.49) MAPK14HPGDRAB9ASMN1; SMN2MAPK13
SCHEMBL1643623 0.86 MAPK14 (0.53) MAPK14LMNARORBRECQLKMT2A
SCHEMBL1642370 0.84 MAPK14 (0.46) MAPK14L3MBTL1MAPK13MAPK12MAPK11
SCHEMBL1643481 0.81 MAPK14 (0.61) MAPK14HPGDRAB9AKMT2AUGCG
SCHEMBL1643526 0.78 RORB (0.51) MAPK14MAPK13MAPK12MAPK11LMNA
SCHEMBL1643035 0.78 UGCG (0.48) RAB9ASMN1; SMN2LMNAKMT2AUGCG
SCHEMBL1643793 0.77 NPC1 (0.46) MAPK14RAB9ASMN1; SMN2LMNAUGCG
SCHEMBL1642040 0.77 MAPK14 (0.51) MAPK14HPGDRAB9ASMN1; SMN2MAPK13
SCHEMBL6939299 0.76 RAB9A (0.48) HPGDRAB9ASMN1; SMN2LMNARORB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098298-A1 New Pyridin-3-Amine Derivatives LABORATORIOS ALMIRALL, S.A. (ES) 2011-04-28 US claimed
US-20110098298-A1 New Pyridin-3-Amine Derivatives LABORATORIOS ALMIRALL, S.A. (ES) 2011-04-28 US disclosed
EP-1987005-A2 NEW PYRIDIN-3-AMINE DERIVATIVES Laboratorios Almirall, S.A. (ES) 2008-11-05 EP disclosed
WO-2007096072-A2 NEW PYRIDIN-3-AMINE DERIVATIVES LABORATORIOS ALMIRALL, S.A. (ES) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098298-A1 New Pyridin-3-Amine Derivatives MAPK1, MAP4K2, MAPK3 MAPK14 33/4885HPGD 954/4885RAB9A 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.